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Counteracting muscle wasting in HIV-infected individuals
WD Dudgeon,1 KD Phillips,2 JA Carson,1 RB Brewer,1 JL Durstine1 and GA Hand1
1Department of Exercise Science, Arnold School of Public Health, and 2College of Nursing, University of South Carolina,
Columbia, SC, USA
HIV-infected persons often experience a loss of lean tissue mass, which includes decreases in skeletal
muscle mass. This HIV-associated wasting is significant because it has been associated with
accelerated disease progression and increased morbidity. Signalling related to several circulating
molecules, including tumour necrosis factor (TNF)-a, growth hormone, insulin-like growth factor
(IGF)-1 and testosterone, has been associated with the aetiology of muscle wasting. Additionally,
nutritional status related to malnutrition and specific dietary deficiencies may be involved. In an
attempt to counter muscle wasting in HIV-infected persons, treatments have been suggested that
target these mechanisms. Nutritional supplementation, cytokine reduction, hormone therapy and
resistance exercise training are potential treatments for this condition. Resistance exercise training,
which is more easily accessible to this population than other treatments, holds promise in
counteracting the process of HIV wasting, as it has been successfully used to increase lean tissue
mass in healthy and clinical populations. This review will explore the HIV/AIDS muscle-wasting
syndrome, its aetiology, and the treatments used to counteract wasting.
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Introduction
The Centers for Disease Control and Prevention define HIV/
AIDS wasting syndrome as an involuntary weight loss of
greater than 10% baseline body weight during the previous
12 months or a 5% loss of weight during the previous
6 months. It has been estimated that nearly 20% of those
infected with HIV suffer from wasting, even with the
widespread implementation of highly active antiretroviral
therapy (HAART) [1]. The wasting in HIV/AIDS is
characterized by reductions in lean body mass or fat-free
mass [2]. Skeletal muscle represents between 50 and 54% of
lean body mass [3,4], and thus wasting is accompanied by
decreased muscular strength and functional performance,
and is associated with disease progression [2]. Fever
(documented for more than 30 days), chronic weakness
and/or chronic diarrhoea (two loose stools or more per day
for at least 30 days), independent of any conditions other
than HIV infection, are common with this syndrome and
may lead to the observed weight loss [5]. Lean body mass
loss can occur independent of total body weight changes,
making the diagnosis of this condition even more difficult.
This type of loss has been described as cachexia, but this
new classification has yet to be fully accepted in the
treatment and diagnosis of HIV/AIDS wasting [6].
The significant loss of metabolically active lean tissue
greatly increases morbidity and mortality [5]. Both before
and after the introduction of HAART, there has been a strong
association between wasting and negative outcomes includ-
ing increased mortality [7], impaired functional status [6],
and accelerated disease progression [8]. HIV-infected
persons also demonstrate a progressive depletion of body
cell mass (intracellular mass of all metabolically active
tissues in the body) near death, and body cell mass and body
weight at death have been found to be only half the ideal
values [9]. HIV RNA levels also correlate positively with
weight loss and body mass index. However, an inverse
relationship exists between CD4 lymphocyte cell counts and
weight loss [10]. In the light of the significant impact of
wasting in HIV-infected persons, research has addressed this
syndrome in the hope of improving the health of those with
HIV wasting. This review will investigate the proposed
aetiologies of HIV/AIDS wasting and the effectiveness of
current treatments in counteracting HIV/AIDS wasting.
Aetiology of HIV/AIDS wasting
The aetiology of the HIV-associated wasting syndrome is
yet to be fully defined, but potential contributing factors
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include malunitrition, abnormal cytokine production and
endocrine dysfunction (Table 1). Thus, it appears that there
are numerous interactions influencing protein turnover, an
integral component of lean tissue maintenance [11]. Protein
turnover is normally balanced between protein degradation
and protein synthesis, which allows lean tissue mainte-
nance. During muscle wasting in HIV/AIDS there is a shift
towards excess protein breakdown [12]. Therefore, wasting
treatments should aim to decrease protein degradation and/
or stimulate protein synthesis.
Malnutrition
Altered metabolism
Elevated resting energy expenditure (REE) is commonly
found in HIV-infected individuals [13–15], and can be 10
to 35% higher than in uninfected controls. In fact, during
periods of acute opportunistic infection, conditions such as
infection with Pneumocystis carinii, Mycobacterium avium
complex (MAC) and cytomegalovirus (CMV) can all cause
further increases in REE [13,16,17]. Gender may play a role
in the altered metabolic response to chronic HIV infection,
as asymptomatic HIV-infected men demonstrate higher
REE values than asymptomatic HIV-infected women [18].
Finally, elevated REE is seen in patients presenting with
lipodystrophy compared with HIV-infected patients with
no signs of this syndrome [19].
Enteropathy
Disease of the digestive tract is referred to as enteropathy.
There is a high prevalence of gastrointestinal (GI) disorders
in the HIV-infected population and these can include
swallowing disorders (47%), abdominal pain and cramping
(20%), diarrhoea (77%), oral and perianal disease (74%),
oral lesions (54%), oral candidiasis (34%) and hairy
leucoplakia (27%) [20–22]. Xerostomia (dry mouth), caused
by infections, medications, smoking and dehydration, is
also found in many HIV-infected persons (29%) [23]. Saliva
is essential to normal digestion and immune function as
it contains enzymes (lingual lipase and salivary amylase)
and immune cells [producing antibodies, immunoglobulin
A (IgA) and salivary leucocyte protease inhibitor] respon-
sible for neutralizing parasites, bacteria and viruses;
therefore, decreased saliva production can contribute to
disorders of digestion and malabsorption, as well as
increase the risk of opportunistic infections.
Alterations of the intestinal lining make infected persons
more susceptible to infections and diarrhoea, thereby
decreasing nutrient absorption [24,25]. HIV itself can cause
atrophy of digestive tract villi, decreasing the surface area
through which absorption takes place. The resultant
decrease in intestinal enzyme activity can cause further
maldigestion, diarrhoea and steatorrhoea (fatty stool)
[26,27]. Diarrhoea can exacerbate symptoms of dehydra-
tion, further decreasing saliva production and increasing
the incidence of malnutrition and secondary infection.
Physical impairment
Physical impairment in this context refers to a decreased
ability to physically chew and swallow food and a
decreased ability to perform activities of daily living
related to nutrition and hygiene. Oral and oesophageal
conditions common in this population can make swallow-
ing painful, and oral and oesophageal lesions can cause
dysphagia and anorexia by physically blocking the glottis
and limiting the size of the oesophagus [20,28]. Fatigue
and reduced functional capacity are often found in this
population and have been shown to decrease the ability of
the HIV-infected individual to complete essential activities
of daily living, such as preparing meals or shopping for
nutritious foods [29].
Neurological impairment
HIV/AIDS-related nerve complication occurs throughout
the course of the disease, often causing dementia, sensory
impairments and neuropathy. Dementia occurs at later
stages of the disease in up to 50% of HIV-patients [30], and
this decreased mental capacity may result in forgetting
to eat and poor medication adherence [31]. Some HIV-
infected individuals experience visual and olfactory
decrements secondary to cranial nerve damage. Sensory
impairments can make foods look, taste and smell different,
reducing hunger and placing patients at risk for malnutri-
tion [32]. Neuropathy of the cranial nerves, usually
occurring later in the course of the disease and associated
with CMV co-infection, is another potential cause of
functional impairment [33]. Loss of cranial nerve function
responsible for chewing, taste, swallowing and salivary
gland stimulation (cranial nerves V, VII and IX) can prevent
complete mastication, cause food to be dry and tasteless,
and prevent completion of the normal swallowing reflex.
Medication-related side effects
HIV-infected individuals are on complex antiretroviral
drug regimens. While these combinations help keep CD4
cell counts high and decrease viral load, HAART causes GI
disturbance and leads to nutritional deficiencies. In fact,
the most common side effects reported with HIV medica-
tions are diarrhoea, anorexia, vomiting, abdominal pain
and cramping, steatorrhoea and GI upset, all of which
affect calorie consumption and nutrient absorption.
Cytokines
Several cytokines, in particular tumour necrosis factor
(TNF)-a, have been implicated in skeletal muscle degra-
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dation. In HIV/AIDS [34], as well as other diseases such as
cancer [35], chronic obstructive pulmonary disease (COPD)
[36] and congestive heart failure [37], skeletal muscle
catabolism has been attributed to TNF-a. TNF-a can inhibit
the secretion of the hormone testosterone, which regulates
muscle mass, affects tissue sensitivity to hormone signal-
ling, and directly stimulates protein degradation [38,39].
Serum concentrations of soluble TNFs 55 and 75, which
reflect TNF-a release, are elevated in HIV-infected patients
compared with healthy control subjects [40]. In HIV-
infected men, circulating TNF-a has been shown to be
inversely associated with changes in lean body mass [41].
Cortisol
Those infected with HIV experience changes at multiple
levels of the hypothalamic pituitary adrenal axis (HPAA),
resulting in elevated cortisol levels [42]. The chronic stress
experienced by these persons along with the elevation of
TNF-a leads to activation of the HPAA, causing excess
cortisol release [43]. Cortisol is a potent catabolic hormone,
which increases rates of protein degradation and slows
protein synthesis rates, especially in skeletal muscle, and
thus is implicated in the wasting associated with HIV
infection [43].
Growth hormone/growth factors
Growth hormone maintains bone and skeletal muscle mass
through the stimulation of insulin-like growth factor (IGF)-
1 release from the liver. IGF-1, an anabolic agent active
in the regulation of protein metabolism, has been shown
to stimulate replication and differentiation of myogenic
(muscle) precursor cells necessary for muscle growth and
repair [44]. Additionally, IGF-1 produced locally in the
muscle is a potent regulator of muscle mass [45]. Growth
hormone release is depressed in obese persons and
malnourished persons suffer from growth hormone resis-
tance as a result of impaired IGF-1 signalling. Therefore,
HIV-induced lipodystrophy and nutrient malabsorption
can cause significant alterations in growth hormone and
IGF-1 function that will ultimately influence lean tissue
mass. Persons with HIV/AIDS wasting also demonstrate
growth hormone resistance, which manifests itself in
increased growth hormone levels and decreased IGF-1
levels, and may be attributable to malnutrition [46]. Thus,
alterations in growth hormone release and utilization
present in HIV/AIDS wasting may be attributable to
malnutrition and/or lipid disorders.
IGF-1 can exert its function by directly binding to the
IGF-1 receptor, but its action can be modified by IGF-
binding proteins (IGFBPs). These IGFBPs, of which there are
six, can enhance or inhibit the biological activity of IGF-1
[47]. IGFBP-3 is the major binding protein in the
circulation and is responsible for binding 90% of IGF-1,
ensuring efficient delivery of the hormone to target tissues.
HIV infection can increase the proteolysis of IGFBP-3,
thereby decreasing IGFBP-3 levels. This may explain the
lack of growth hormone-induced increase in IGF-1 seen in
HIV-infected persons, and possibly contribute to a decrease
in protein synthesis that may lead to muscle wasting [48,49].
Testosterone
Decreased circulating testosterone levels also correlate with
body mass loss, lean tissue mass loss, and decreased
exercise capacity in HIV-infected persons [46]. Thirty to
50% of HIV-infected men may suffer from low testosterone
levels, which puts them at greater risk for muscle wasting
[49]. Testosterone is a potent regulator of skeletal muscle
mass that acts via multiple pathways. Testosterone binds to
skeletal muscle receptors, thus directly influencing protein
expression [50]. Testosterone stimulates the release of
growth hormone from the pituitary, thereby increasing the
expression of IGF-1, resulting in increased protein synth-
esis [51]. Additionally, testosterone can influence lean
tissue mass by exerting an antiglucocorticoid (anticata-
bolic) effect [52].
Treatments for muscle wasting
It has been proposed that many factors are involved in the
mechanisms that lead to the muscle wasting observed in
HIV/AIDS. No definitive aetiology has been established,
and, given the interactive nature of the proposed mechan-
isms of muscle wasting, it is likely that the cause is
multifactorial. Therefore, numerous treatments for HIV/
AIDS muscle wasting have been proposed and studied.
These treatments include nutritional interventions, hor-
mone therapy, cytokine treatments and resistance exercise
training (Table 2).
Nutritional strategies
Nutritional counselling for 8 weeks, resulting in an increase
in calorie intake of 600 kcal/day, was shown to increase fat
free mass in HIV-infected patients (n5 24) with recent
weight loss (45%). Supplementation with a high-calorie
drink (n5 26) also increased fat free mass in HIV-infected
persons [53]. HIV-infected malnourished patients given
supplementation with a polymeric diet (containing a
balance of standard nutrients) also demonstrated signifi-
cant increases in body weight, fat mass (skin fold
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measurement), energy balance and nitrogen balance
following a 45-day intervention [54].
In five malnourished (as a result of absorption or food
intake problems) AIDS patients, body cell mass was
significantly increased, as were body weight and body fat
content, following 4–42 weeks of home total parenteral
nutrition (as many calories as tolerated up to 35 kcal/kg of
body weight) [55]. The same intervention in seven subjects
with wasting caused by severe systemic infections resulted
in increases in body weight and fat mass, but not lean
tissue mass. These data, collected prior to the introduction
of HAART, showed that nutritional support is successful at
countering weight loss by restoring fat mass, and possibly
lean tissue mass. However, common side effects of HAART
include nausea, vomiting and diarrhoea, which can
decrease appetite and alter nutrient absorption. Thus, its
effectiveness at restoring body weight in HIV-positive
persons receiving HAART is unknown.
Other nutritional treatments aimed at combating muscle
wasting in HIV-infected individuals have focused on
specific deficiencies within the diet, rather than overall
caloric intake. The need for L-glutamine, an essential
amino acid that is required for protein synthesis, exceeds
the rate of production during stress and inflammation, and
thus skeletal muscle is catabolized to provide this necessary
amino acid to other parts of the body [56]. L-glutamine
is also necessary for many other metabolic processes,
including tissue repair, but to complete its function it must
be present with other necessary amino acids. Most
parenteral nutrition solutions and enteral feeding formulas
do not contain L-glutamine, potentially explaining their
lack of success in increasing lean tissue mass. Additionally,
reactive oxygen species have been found to be associated
with HIV/AIDS wasting and overall weight loss [57]. In
the light of these findings, a combined L-glutamine
and antioxidant supplement was administered to 21 HIV-
infected individuals with documented wasting (45%) for
12 weeks. Subjects receiving the treatment increased body
weight by 2.2 kg compared with a nonsignificant 0.3-kg
gain in the controls. Bioelectrical impedance analysis (BIA)
revealed a significant increase of 1.8 kg in body cell mass
versus a 0.4-kg change in the controls. No changes in diet
were found according to a 3-day dietary recall [58].
Eighteen of the 21 subjects were receiving HAART, and the
subjects did not report any side effects during the study.
A mixture of beta-hydroxy-beta-methylbutyrate (3 g),
L-glutamine (14 g) and L-arginine (14 g) was used as a
nutritional supplement in patients with AIDS (all receiving
antiretroviral therapy) who had muscle wasting [59]. Beta-
hydroxy-beta-methylbutyrate is thought to provide pro-
tective benefits to skeletal muscle by limiting proteolysis
[60], while L-arginine is a precursor to nitric oxide, which
may have nitrogen-sparing effects [61]. Treatment subjects
(n5 22) received supplements twice daily for 8 weeks,
while control subjects (n5 21) received a placebo contain-
ing maltodextrin (easily digestible carbohydrates). The
treatment subjects gained 3.0  0.5 kg body weight com-
pared with 0.37  0.84 kg (P5 0.009) in the control
subjects. There was no change in fat mass in either group
(P40.20), and computed tomography (CT) scans revealed
that the increase in body weight in the treatment group was
predominantly lean body mass (2.55  0.75 kg) compared
with a loss of lean tissue ( 0.70  0.69 kg; P5 0.003) in
the controls [59]. Even with the limited published
Table 1 Anabolic and catabolic factors associated with HIV/AIDS wasting
Agent Action Implications in HIV/AIDS wasting
Anabolic agents
Testosterone " developmental protein expression Testosterone is decreased in men with wasting
Stimulation of growth hormone release
Antiglucocorticoid effects
Growth hormone " protein synthesis Growth hormone resistance has been observed in wasting,
resulting in decreased IGF-1 production" collagen synthesis
Stimulation of release of IGF-1
Insulin-like growth factor-1 " protein synthesis IGF-1 is decreased in wasting
Stimulation of replication and differentiation Increased degradation of binding proteins in wasting leads to
of muscle precursor cells decreased IGF-1 activity
Catabolic agents
Tumour necrosis factor a Stimulation of protein degradation TNF-a levels are elevated in wasting
Alteration of hormone receptor sensitivity
Decrease in anabolic hormone levels
Indirect stimulation of cortisol release
" in resting energy expenditure
Cortisol Inhibition of protein synthesis Elevated cortisol levels are common in persons with wasting
" protein degradation
" proteolytic enzymes
IGF, insulin-like growth factor; TNF, tumour necrosis factor.
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information, these results indicate that correcting specific
dietary deficiencies may be effective in restoring lean
tissue mass in HIV-infected persons. However, no federally
funded programmes for identifying and treating nutritional
deficiencies in HIV-infected persons exist, and thus the
practicalities of analysing and prescribing corrective
nutrition to large numbers of HIV-infected persons are
questionable.
Hormone therapy
Testosterone
Administration of testosterone has resulted in increased
muscle mass and strength in several clinical populations,
including hypogonadal elderly men [62], COPD patients
[63] and persons with autoimmune diseases receiving
glucocorticoids [64]. Testosterone therapy therefore has
potential for treating HIV/AIDS muscle wasting. Kong and
Edmonds [65] reviewed the effects of testosterone therapy
in HIV wasting. This meta-analysis revealed that oral
testosterone administration resulted in increases in body
cell mass [mean 1.22 kg; 95% confidence interval (CI) 0.23
 2.22 kg] for all groups, but those who received intra-
muscular injections experienced a greater increase (mean
1.99 kg; 95% CI 0.23–3.76 kg). An interesting finding was
that only one trial included women [66], and if they were
excluded from the analysis the change in body cell mass
increased even further (mean 2.63 kg; 95% CI 1.42–
4.06 kg). There was an overall mean increase of 1.04 kg
(95% CI  0.01 to 2.10 kg) in total body weight, and again
exclusion of women produced greater increases (mean
1.54 kg; 95% CI  0.03 to 3.10 kg). The assessment of
muscle function/strength was not uniform across the
reviewed studies, making meta-analysis for this variable
impossible; however, three of the studies reported an
improvement in strength [67–69]. Because of reporting
inconsistencies, meta-analysis of adverse events was
impossible to assess, but the authors indicate that the most
common reports were of acne, gynaecomastia and breast
tenderness. Overall, analysis was difficult because of
heterogeneity of participants (in terms of gender, age,
pre-intervention testosterone level, etc.), treatments (mode
of delivery and dosage) and outcome measures (lean tissue
mass vs body cell mass). However, the reviewed literature
indicates that testosterone therapy can positively influence
lean tissue mass and total body weight in those with HIV/
AIDS wasting [70].
Nandrolone decanoate
Another anabolic steroid, nandrolone decanoate (ND), a
testosterone analogue, appears to be effective in increasing
lean tissue mass and muscular strength in men with HIV
infection. The rationale for using ND in treating HIV/AIDS
wasting is that it has high androgenic/anabolic activity
accompanied by fewer androgenic side effects than
testosterone. A 12-week regimen of intramuscular ND
administration increased lean tissue mass [3.9  2.3 kg;
dual energy X-ray absorptiometry (DXA)], body cell mass
(2.6  1.0 kg; BIA) and quadriceps and hamstring muscle
area [Po0.001; magnetic resonance imaging (MRI)] in
15 subjects (most receiving antiretroviral therapy) [71].
The subjects receiving ND significantly improved strength
from baseline in eight of nine exercises as determined by
one repetition maximum (1-RM) lifts. Side effects of the
therapy included development of acne (one subject) and
testicular shrinkage (eight subjects). Subjects with AIDS-
related wasting (mean CD4 count 90  24 cells/mL;45%
weight loss) with low testosterone (o25th percentile for
age) received a low dose (65mg/week) or a high dose
(195mg/week) of ND over a 14-day period [72]. They were
found to show an increase of 0.5 or 0.9 kg in lean tissue
mass per week, respectively, and the increased lean tissue
correlated with significant nitrogen retention.
Gold et al. examined the use of ND in patients (n5 17)
with HIV-related wasting (5–15% loss of body weight) who
were unable to gain weight via nutritional therapy and
education [73]. Following 16 weeks of bi-weekly 100mg/
mL intramuscular ND injections, anthropomorphic, BIA,
total body water and neutron activation measurements
revealed significant increases in body weight (mean
0.14 kg/week) and lean body mass (mean 3 kg overall).
The results indicate that ND supplementation appears to
be effective at increasing weight in HIV-infected persons
with wasting, and a significant portion of this weight gain
is lean tissue mass.
Growth hormone
Growth hormone therapy is another strategy used in the
treatment of HIV/AIDS wasting. Short-term (7 days)
administration of growth hormone to six HIV-infected
persons (pre-HAART) with wasting (average 19% below
ideal body weight) resulted in increased body weight
(2.0  0.3 kg) and decreased urinary nitrogen excretion
(288  17mmol/day), despite increased resting energy
expenditure (7.5%). These results indicated that short-term
growth hormone administration was able to increase
protein anabolism and body weight, which theoretically
will result in increased body cell mass with long-term
administration [74]. These results were attained pre-
HAART, so the outcomes must be viewed cautiously given
the influences of HAART on fat distribution [75] and
skeletal muscle function [76].
Growth hormone at a low dose (1.4mg/day) was
administered to patients who had progressed to AIDS
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(CD4 counto200 cells/mL) and were suffering from wasting
(410% weight loss) [77]. After 6 weeks of treatment the
growth hormone group (n5 12) significantly increased
lean body mass (P5 0.002) and body weight (P5 0.02);
however, at 3 months subjects no longer showed sig-
nificant changes in lean body mass or weight. Muscle
function, assessed by computerized isotonic dynamometry,
with muscular power as the endpoint measure of interest,
revealed that the growth hormone group had increased
upper body and lower body power at 6 weeks, but only
upper body power at 12 weeks. Given the small number of
subjects and the significant side effects of the growth
hormone therapy (jaw pain, n5 4; myalgia/arthralgia,
n5 4), the results of this study should be interpreted with
caution.
Growth hormone administered at a dose of 0.1mg/kg/
day to HIV-infected persons with documented wasting
(410% loss of ideal body weight) for 3 months resulted in
significant increases in weight and lean body mass
(Po0.001) [78,79]. Subjects who received the same dose
for 6 months showed no difference (P5 0.25) in lean tissue
mass compared with those who received 3 months of
growth hormone [79]. This dose also resulted in a
significant improvement (P5 0.039) in work output (cycle
ergometer) after 3 months [78]. Side effects occurred in 15
of the 90 subjects randomized to receive growth hormone,
with arthralgia, myalgia, fluid retention and diarrhoea
being the most commonly reported side effects [78]. These
data indicate that increases in lean body mass can be
sustained, and the most significant effects of growth
hormone, both on lean tissue mass and on muscular
strength, are observed in the early phases (3 months) of
treatment.
A low dose of growth hormone (30–40 mg/kg/day) was
tested for 6 months in HIV-infected persons (n5 5) during
the HAART era [80], and increases in lean body mass
(62.9  6.4 to 68.3  9.1 kg; P5 0.03) were observed in a
comparison of baseline and 6-month results. It should be
noted that arthralgia, oedema in the extremities, and
fasting hyperglycaemia did develop in these subjects to the
extent that some had to reduce the growth hormone dose to
1.5mg/day. These data show that increases in lean body
mass with growth hormone administration can be attained
at lower dosages, and can be expected in persons receiving
HAART.
In a study that included patients on HAART, a high dose
of growth hormone (6mg/day) was administered for 6
months, a 12-week wash-out period was implemented, and
then 4mg of growth hormone was administered every
other day for 6 months [81]. The primary goal of the study
was to observe changes in body fat, but DXA scans also
revealed an increase in lean tissue mass during the high-
dose intervention, at 3 months (60.7  9.7 kg at baseline vs
65.8  10.8 kg at 3 months) and at 6 months (66.0 
11.3 kg) (n5 19). The low-dose intervention (n5 9) also
produced increases in lean tissue mass at 3 months
(60.6  8.6 kg at the start of the low-dose treatment vs
63.4  7.2 kg at 3 months) and at 6 months (63.2  8.3 kg),
although the changes were not as great as in the high-dose
treatment. Nine subjects experienced adverse events during
the high-dose phase to the extent that dosages were
reduced, and 13 participants experienced side effects at
some point during the study.
Insulin-like growth factor-1
Research has revealed that IGF-1 is not as effective as
growth hormone at increasing nitrogen retention [82] and
subjects frequently experience hypoglycaemic effects
along with myalgia, gynaecomastia and headaches. Ad-
ditionally, IGF-1 administration has only shown transient
increases in lean tissue mass, with no apparent improve-
ments in muscle function [77]. However, the combination
of growth hormone and IGF-1 has produced a lean tissue
mass increase of 3.2 kg, which is greater than the increase
obtained with either agent alone in these studies [83,84].
Limited data are available regarding the effects of IGF-1
on increasing lean tissue mass, and thus it is too early to
speculate on its effectiveness.
Cytokine treatments
Research has shown that proinflammatory cytokines
(specifically TNF-a) can induce catabolic pathways in
skeletal muscle and suppress the expression and function
of the anabolic hormone IGF-1 [85]. Additionally, TNF-a
has been shown to be elevated in patients with AIDS and
AIDS-related weight loss [86]. Thus, cytokine therapies
may be beneficial in combating muscle wasting in HIV-
infected individuals. Treatment with thalidomide (which
suppresses TNF-a production in vitro) has demonstrated
effectiveness in promoting weight gain in patients with
HIV disease [87]. Twenty-eight AIDS patients with
documented wasting (410% loss) on antiretroviral therapy
received either 400mg of thalidomide (n5 14) or placebo
(n5 14) daily for 12 weeks [88]. Significant weight gain
was seen in eight (57%) treatment subjects while only one
placebo subject gained weight. Shorter treatment periods
(14 days) with thalidomide in HIV-infected subjects with-
out wasting also increased body weight (P5 0.002) [89].
This weight gain was associated with increased nitrogen
retention (P5 0.017), suggesting that a portion of the
weight gain may be lean tissue mass.
Pentoxifylline, another cytokine modulator, decreases
TNF production and has been effective in decreasing TNF
mRNA levels as a result of thrice-daily doses in AIDS
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patients [90]. Ketotifen, an inhibitor of TNF-a release from
peripheral blood mononuclear cells, has also been used as a
treatment in HIV-infected individuals. Daily doses of
ketotifen for 12 weeks resulted not only in decreased
TNF-a release, but also in weight gain [91]. Thus, thalido-
mide, pentoxifylline and ketotifen appear to be effective in
increasing body weight, but the effects on lean tissue mass
and muscle function are yet to be characterized.
Resistance exercise training
Resistance exercise training is known to increase skeletal
muscle mass and strength in numerous healthy and clinical
populations regardless of gender, age or race [92].
Resistance exercise serves to improve muscle protein
balance via a number of mechanical and chemical signals,
and therefore maintains and/or increases muscle mass [93].
Thus, resistance exercise training has the potential to be
a viable alternative to pharmacological treatments for
maintaining and increasing lean body mass and muscular
strength in HIV-infected persons.
Resistance training programmes have been used to
combat muscle wasting in many clinical populations. A
12-week total body resistance training programme (three
sets of eight repetitions at 80% of 1-RM, three times per
week) involving patients (17 men and 19 women, over 50
years of age) with renal failure resulted in increases in total
body potassium and muscle fibre cross-sectional area
(muscle biopsy), and improvement in muscle strength
compared with controls [94]. Similarly, Hakkinen et al. [95]
implemented a 2-year total body resistance training
programme (two sets of 8–12 repetitions, two times per
week at 50–70% of 1-RM) for rheumatoid arthritis patients
(31 subjects; 18 women). Those who completed the exercise
training regimen exhibited significant increases in strength
(19–59%); however, lean tissue measurements were not
taken.
Prior to discussing the effects of exercise in HIV-infected
populations, it should first be recognized that research has
shown exercise to be safe in this population [96]. Exercise
at low to moderate intensities does not increase the
prevalence of opportunistic infections, does not increase
viral load, and does not decrease CD4 cell counts [97].
Additionally, there have been no reports of adverse side
effects to exercise interventions. That being said, as is the
case in other clinical populations, the benefits of resistance
exercise are also experienced by HIV-infected patients.
Progressive resistance exercise programmes have resulted
in increases in lean tissue mass and improvements in
strength in HIV-infected persons, both with and without
muscle wasting.
Roubenoff et al. [98] implemented an 8-week resistance
exercise training programme in a group of 21 HIV-infected
persons receiving antiretroviral therapy. The protocol
consisted of three sets of eight repetitions at 50% of 1-RM
during week 1, 60% of 1-RM during week 2, and 75–80% of
1-RM during the remaining weeks on both upper body and
lower body exercises. Significant strength improvements
(18–31%) were reported on all exercises, along with a
significant increase (Po0.0002) in lean body mass (DXA).
Roubenoff and Wilson also found that differential effects
occurred between the wasting and nonwasting groups [99].
The subjects with muscle wasting had 16% greater strength
increases and gained 3% more lean tissue mass. Another
interesting finding was that both groups increased perceived
physical functioning following the intervention.
Resistance exercise training and hormone therapy
A common trend in studying HIV/AIDS-associated wasting
is combining resistance exercise training with androgen
therapy. Bhasin et al. [68] tested the effects of a 16-week
training programme (three times per week alternating
between heavy days of four to six repetitions at 90% 1-RM
and moderate days of four to six repetitions at 70% 1-RM)
combined with testosterone supplementation in a group of
HIV-positive men with wasting (5% or greater loss of body
weight). Results showed that both exercise (29–36%) and
testosterone therapy (17–28%) increased strength and both
exercise (Po0.03) and testosterone (Po0.001) increased
thigh muscle volume (CT). The interesting finding was that
there was not an additive effect with the combination of
therapies.
Sattler et al. [71] examined the effects of ND therapy and
a resistance exercise training programme in HIV-infected
men (n5 30) over 18 years of age. After a 12-week period
in which the exercise group performed three sets of eight
repetitions at 80% 1-RM, the ND-only group showed
increased lean tissue mass (3.9  2.3 kg; DXA) and
increases in quadriceps (Po0.001) and hamstring
(Po0.001) muscle area (MRI). The exercise and ND group
experienced the same increases in muscle area, but had an
even greater increase in lean body mass (5.2  5.7 kg).
Grinspoon et al. [67] tested the effects of testosterone
and exercise for 12 weeks in a group of HIV-infected men
with wasting. Subjects randomized to receive the exercise
intervention completed 20min of aerobic exercise followed
by two sets of eight repetitions at 60% 1-RM during the
first week, and then progressed to three sets of eight
repetitions at 80% 1-RM during the final weeks. There was
an increase in lean body mass (DXA) in the training group
(mean 2.3 kg) and in the combined therapy group (mean
4.0 kg), showing an effect of testosterone; however,
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isometric strength tests showed that neither training nor
testosterone had a significant effect on muscle strength.
Summary
It is evident from the data presented above that there exist
many methods of increasing lean tissue mass and
improving muscular strength in HIV-infected persons both
with and without wasting (Table 2). Basic nutritional
supplementation, while accessible to many persons,
appears to result in increased body weight, but mainly
via increases in body fat stores. Other nutritional inter-
ventions, such as those that analyse dietary intake and
supplement for specific amino acid deficiencies, can
increase lean tissue mass in HIV-infected populations;
however, the availability of these types of services limits
the applicability of this type of intervention.
Blocking catabolic factors, such as TNF-a, with the use
of pharmacological agents has been effective at increasing
body weight in HIV-infected persons. Further research
is needed, however, to determine whether these increases
in weight are attributable to lean tissue or fat mass gains.
Furthermore, this population is already burdened with
medications for treating HIV infection, so the feasibility of
administering additional drugs is questionable. Finally, this
population already experiences decreased immune func-
tion. Therefore, decreasing TNF-a, which is a vital cytokine
in the innate immune system, may lead to additional
immunological complications.
Results indicate that growth hormone at higher doses
(0.1mg/kg/day) provides benefits to those with HIV/AIDS
wasting, regardless of disease severity, by increasing
protein anabolism and thus increasing lean tissue mass.
An inconsistency, however, is the relationship between the
increased lean tissue mass and muscle function. Addition-
ally, it is unclear if these increases in lean body mass are
actually skeletal muscle, because it has yet to be verified
that these increases are concurrent with increases in muscle
function. The major limitation of this research is that many
of the studies occurred before the HAART era, and thus
results must be cautiously interpreted. Additionally, while
the listed side effects may not seem severe, if added to the
side effects of HIV infection itself, and those of HAART,
they may be considered too burdensome. Finally, growth
hormone costs approximately $42/mg, making the average
cost $252/day, or $21 000 for a 12-week treatment course.
This makes growth hormone inaccessible to most HIV-
infected persons.
Androgen therapy, with either testosterone or ND, has
been successful in increasing lean tissue mass and mus-
cular strength in HIV-infected persons with and without
wasting. A minimal effective dose is yet to be determined,
and this is a significant hurdle because the side effects
(gynaecomastia, acne and breast tenderness with testoster-
one and acne and testicular shrinkage with ND) can further
decrease the quality of life in this population, who already
experience HIV-related problems and antiretroviral treat-
ment-related side effects. Further, research has yet to show
the effects of treatment cessation (e.g. endogenous
testosterone production, lean tissue mass changes and
mood alterations), which could place these persons in even
more compromising situations than prior to therapy.
Exercise training studies, although few in number, show
that resistance exercise training at high intensities (80%
1-RM) for relatively short periods is successful at increas-
ing lean tissue mass in HIV-infected patients with and
without wasting. These improvements in lean tissue mass
are also associated with significant increases in muscular
performance, as evidenced by gains in muscular strength.
Also, these beneficial effects occur without compromising
immune function and are independent of the side effects
common to hormone therapies.
Table 2 Effects of various therapies on body composition and muscular strength in HIV-infected persons with wasting
Therapy
Treatment duration
(weeks)
Results
Side effectsWeight LTM FM BCM
Muscular
strength
Total parenteral nutrition 4–42 " NC " " – None reported
L-glutamine 12 " – NC " – None reported
Testosterone/nandrolone decanoate " " – " " Acne, gynaecomastia, breast tenderness,
testicular shrinkage
Growth hormone/IGF-1 fasting 1–24 " " – – NC Jaw pain, myalgia, arthralgia, oedema,
hyperglycaemia, diarrhoea, headaches
TNF-a blockers interference 2–12 " – – – – Potential innate immune system
Resistance exercise 8 " " – – " None reported
Resistance exercise and testosterone 8–16 " " NC – " See testosterone side effects
LTM, lean tissue mass; FM, fat mass; BCM, body cell mass; " , increase following therapy; NC, no change following therapy; –, not measured; IGF, insulin-like
growth factor; TNF, tumour necrosis factor.
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Conclusions
Muscle wasting in HIV/AIDS is a major public health
problem because the loss of muscle mass is a predictor of
morbidity and mortality, and the corresponding decline
in muscular strength can be debilitating. Nutritional thera-
pies, pharmacological agents that decrease TNF-a levels,
androgen supplementation, growth hormone administra-
tion and resistance exercise have all shown varying levels
of success in increasing lean tissue mass in HIV-positive
persons. However, resistance exercise appears to be a very
effective treatment because it is less expensive than other
treatments, debilitating side effects are virtually nonexis-
tent, and it is available to a far greater portion of the
population. Additionally, quality of life and physical
functioning have also been positively affected by exercise
training programmes.
Given the influence of HAART on body composition and
muscle function, many early exercise and HIV studies need
to be revisited. It is also unknown whether disease status
affects exercise training results. Additionally, the under-
lying mechanism(s) involved in the exercise-induced
increase in lean tissue mass is yet to be defined. Further,
it is yet to be determined whether increases in lean tissue
mass can be attained at lower training intensities, which
may increase retention rates. Finally, no long-term studies
examining the effects of resistance training in HIV-infected
populations exist; it is therefore unknown whether the
benefits can be sustained over time, or whether further
adaptations occur.
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